Welcome to our dedicated page for Aurora Cannabis news (Ticker: ACB), a resource for investors and traders seeking the latest updates and insights on Aurora Cannabis stock.
Aurora Cannabis Inc. (ACB) is a Canada-based global medical cannabis company with shares listed on NASDAQ and the Toronto Stock Exchange. From an investor and industry perspective, Aurora’s news flow centers on medical cannabis expansion, scientific research, international market development and operational performance.
Company announcements frequently highlight growth in global medical cannabis revenue, leadership positions in key markets, and updates on its plant propagation business through Bevo Farms Ltd. Earnings releases and financial updates provide detail on segment performance across medical cannabis, consumer cannabis and plant propagation, along with adjusted gross margins, adjusted EBITDA and working capital trends.
News items also cover Aurora’s international initiatives, such as investments in its EU-GMP manufacturing facility in Leuna, Germany, launches of proprietary medical flower cultivars in Poland under the Cannabis flos Aurora brand, and the introduction of the Daily Special medical brand in Germany. In Australia, updates include distribution partnerships through MedReleaf Australia and Leafio, aimed at expanding access to Aurora’s medical cannabis products via pharmacy networks.
Scientific and educational developments are another recurring theme. Aurora reports progress in powdery mildew resistance research (PM2) conducted at its Aurora Coast R&D facility, including breeding programs and production trials. The company also announces collaborations like the Physician Experience Platform (PEP) with Copeia, which provides anonymized, peer-reviewed medical cannabis case studies for physicians in multiple countries.
Investors following ACB news can expect coverage of quarterly results, international facility investments, product launches, distribution agreements, conference participation and medical education initiatives. Bookmark this page to monitor how Aurora’s strategic focus on global medical cannabis, science and international markets is reflected in its ongoing news and disclosures.
Aurora Cannabis (NASDAQ: ACB) has announced the launch of two new high-potency medical cannabis products in Poland. The company will introduce Farm Gas (27% THC) on June 30 and Sourdough (29% THC) in early August 2025, representing the highest potency medical cannabis products in the Polish market.
Both proprietary cultivars are grown in Aurora's Canadian GACP and EU-GMP facilities. Farm Gas, bred from Sour Diesel and GMO genetics, features a unique terpene profile with limonene and caryophyllene. Sourdough, derived from Cake and Diesel genetics, offers distinct sour and gasoline notes with high THC content.
Aurora Cannabis (NASDAQ: ACB) (TSX: ACB), Canada's largest medical cannabis company, has announced its participation in TD Cowen's 9th Annual Future of the Consumer Conference in New York City. CFO Simona King will engage in a fireside chat and investor meetings on June 3, 2025, at 2:45pm EST.
The discussion, hosted by TD Cowen's VP of Equity Research Derek Lessard, will focus on Aurora's international market expansion, medical cannabis landscape developments, Canadian manufacturing progress, and market dynamics. A live audio webcast will be available, with replay access for approximately 90 days through Aurora's investor relations website.
Aurora Cannabis has completed a $3 million investment in its Pemberton, British Columbia manufacturing facility, now renamed to Aurora Alpine. The multi-year upgrades have significantly improved the facility's performance, combining proprietary genetics with advanced engineering to optimize cultivation conditions.
Key achievements include:
- Doubled yield and potency, reaching 33.7% record levels
- GACP certification enabling international exports
- Enhanced operational efficiency and cultivation precision
The facility, formerly known as Whistler Medical Marijuana Company, was licensed in 2019. Located overlooking Mount Currie in the Pemberton Valley, the renamed Aurora Alpine reflects the company's commitment to excellence in cannabis production. The improvements strengthen Aurora's position as a global leader in medical cannabis, particularly in international markets through its premium product exports.
Aurora Cannabis (NASDAQ: ACB) has launched its first medical cannabis concentrates for patients in the United Kingdom, expanding its global medical cannabis portfolio. The company introduced two proprietary cultivar-specific 1.2g resin cartridges: Sourdough (indica) and Electric Honeydew (sativa).
The inhalable cartridges offer key benefits including exceptional flavor profiles, high potency for consistent dosing, and a user-friendly design for convenient and discreet consumption. The products are manufactured in TGA-GMP certified facilities without additives, ensuring premium quality and safety standards.
This launch follows successful implementations in Canada and Australia, demonstrating Aurora's commitment to expanding patient access to high-quality medical cannabis globally. The products are available nationwide through cannabis retailers, with patients advised to consult their doctors or clinics for more information.
Aurora Cannabis (NASDAQ: ACB) has been recognized on The Globe & Mail's 2025 Report on Business Women Lead Here list for its outstanding executive gender diversity. The company, Canada's largest medical cannabis provider, boasts 43% female representation in its executive leadership team.
The recognition highlights Aurora's commitment to diversity and inclusion, as emphasized by CFO Simona King. In 2022, the company established the Women Empowerment Network (WEN), an employee resource group focused on advancing women's professional development through learning and community engagement opportunities.
This achievement will be featured in the April 2025 issue of Report on Business magazine, distributed with The Globe and Mail on March 29, 2025.